Publications by authors named "Masahiro Tatsuno"

Article Synopsis
  • This study analyzed pharmacokinetic (PK) data for atezolizumab, an immunotherapy drug, in Japanese patients with non-small cell lung cancer (NSCLC), focusing on a dosing regimen of 1200 mg every three weeks.
  • Researchers evaluated data from 262 patients, measuring plasma drug levels before the third treatment cycle and examining how these levels correlated with treatment effectiveness and the occurrence of adverse events (AEs).
  • Findings indicated that lower plasma levels of atezolizumab were linked to shorter overall survival, while higher drug concentrations were associated with increased AEs, suggesting the importance of monitoring PK levels for better treatment outcomes.
View Article and Find Full Text PDF

We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naïve and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety.

View Article and Find Full Text PDF

This study was conducted to explore the relationship between physicochemical property and toxic effectiveness using rat red blood cells (RBCs). The toxic effectiveness of acid nonsteroidal anti-inflammatory drugs (NSAIDs) was systemically examined by the depletion of intracorpuscular adenosine triphosphate (ATP), glutathione (GSH), and hemoglobin (Hb) at various doses, increased every 5 fmol/RBC. When the RBCs were incubated with NSAIDs, the drugs attained maximum levels within RBC, and the levels were then reduced.

View Article and Find Full Text PDF

Propofol (2,6-diisopropylphenol), widely used an intravenous anesthetic, is rapidly metabolized to its glucuronide in the in vivo studies. Kinetic parameters for the glucuronidation of propofol and its analogs, such as 2,5-diisopropylphenol, 2-tert-butyl-6-methylphenol, 2-tert-butyl-5-methylphenol, 2,6-dimethylphenol and 2,5-dimethylphenol, were determined in vitro using human and rat liver microsomes. 2,5-Dimethylphenol and 2-tert-butyl-6-methylphenol exhibited the highest and lowest glucuronidation rates, respectively.

View Article and Find Full Text PDF